Bisphosphonate-induced femoral fragility fractures: What do we know?

References

• Lewinnek GE, Kelsey J, White AA, et al. The significance and a comparative analysis of the epidemiology of hip fractures. Clin Orthop. 1980;152:35–43.
   PubMed Web of Science ®Google Scholar
• Sernbo I, Johnell O. Consequences of a hip fracture: A prospective study over 1 year. Osteoporos Int. 1993;3:148–153.
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16 Suppl 2:S3–S7.
   Google Scholar
• Carlos F, Clark P, Maciel H, et al. Direct costs of osteoporosis and hip fracture: An analysis for the Mexican Social Insurance Health Care System. Salud Publica Mex. 2009;21 Suppl 1:S108–S113.
   Web of Science ®Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733.
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–475.
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet. 1999;353:878–882.
   PubMed Web of Science ®Google Scholar
• Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137(9):1001–1005.
   PubMed Web of Science ®Google Scholar
• Schneider EL, Guralnik JM. The aging of America: Impact on health care costs. JAMA. 1990;263:2335–2340.
   Google Scholar
• Riggs BL, Melton III LJ. The worldwide problem of osteoporosis: Insights afforded by epidemiology. Bone. 1995;17(Suppl): 505S–511S.
   Google Scholar
• Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18(6):805–810.
   PubMed Web of Science ®Google Scholar
• Haussler B, Gothe H, Gol D, et al. Epidemiology, treatment and costs of osteoporosis in Germany – the Bone EVA Study. Osteoporos Int. 2007;18(1):77–84.
   Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark. Osteoporos Int. 2005;16(2):134–141.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16(3):229–238.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6(1):17–23.
   Google Scholar
• Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev. 1998;19(1):80–100.
   PubMed Web of Science ®Google Scholar
• Reid IR. Bisphosphonates. Skeletal Radiol. 2007;36(8):711–714.
   Web of Science ®Google Scholar
• Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–759.
   PubMed Web of Science ®Google Scholar
• Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. Canadian Taskforce on Osteonecrosis of the Jaw. J Rheumatol. 2009;36(3):478–490.
   Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1491.
   PubMed Web of Science ®Google Scholar
• Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess. 2004;8(4):1–176.
   Web of Science ®Google Scholar
• Yan Y, Wang W, Zhu H, et al. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab. 2009;27(4):471–478.
   Web of Science ®Google Scholar
• Cadarette SM, Katz JN, Brookhart MA, et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int. 2009;20(10):1735–1747.
   Web of Science ®Google Scholar
• Seeman E. To stop or not to stop, that is the question. Osteoporos Int. 2009;20(2):187–195.
   Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;7;348(9041):1535–1541.
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;13;282(14):1344–1352.
   Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91.
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE. Curr Med Res Opin. 2005;21(3):391–401.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Sambrook P. Oral nitrogen-containing bisphosphonates: A systematic review of randomized clinical trials and vertebral fractures. Curr Med Res Opin. 2008;24(9):2669–2677.
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial. N Engl J Med. 2007;356(18):1809–1822.
   PubMed Web of Science ®Google Scholar
• Miller PD, Ward P, Pfister T, et al. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: A review. Clin Exp Rheumatol. 2008;26(6):1125–1133.
   Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12(1):1–12.
   PubMedGoogle Scholar
• Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Efficacy and safety results. Osteoporos Int. 2008;19(7):1039–1045.
   PubMed Web of Science ®Google Scholar
• Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–2115.
   Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654–661.
   PubMed Web of Science ®Google Scholar
• Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35(3):488–497.
   PubMed Web of Science ®Google Scholar
• Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006;91(7):2631–2637.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Bauer DC, Cauley A, et al. Efficacy of continued Alendronate for fractures in women without prevalent vertebral fractures: The FLEX trial (Abstract 1057). Presented at the 29th annual meeting of the ASBMR, Sept 16–20, 2007.
   Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al; (FLEX Research Group). Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA. 2006;296(24):2927–2938.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday. Osteoporos Int. 2008;19(11):1613–1620.
   Web of Science ®Google Scholar
• Flora L, Hassing GS, Parfitt AM, et al. Comparative skeletal effects of two bisphosphonates in dogs. Metab Bone Dis. 1980;2(Suppl):389–407.
   Google Scholar
• Flora L, Hassing GS, Cloyd GG, et al. The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res. 1981;3(4–5):289–300.
   Google Scholar
• Hirano T, Turner CH, Forwood MR, et al. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone. 2000;27(1):13–20.
   Web of Science ®Google Scholar
• Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.
   PubMed Web of Science ®Google Scholar
• Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on longterm alendronate. Geriatrics. 2006;61:31–33.
   PubMed Web of Science ®Google Scholar
• Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br. 2007;89:349–353.
   PubMed Web of Science ®Google Scholar
• Cheung RK, Leung KK, Lee KC, et al. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007;13:485–489.
   PubMedGoogle Scholar
• Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury. 2008;39:224–231.
   PubMed Web of Science ®Google Scholar
• Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350.
   PubMed Web of Science ®Google Scholar
• Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy – a case report. Acta Orthop. 2008;79:565–567.
   PubMed Web of Science ®Google Scholar
• Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93(8):2948–2952.
   PubMed Web of Science ®Google Scholar
• Sayed-Noor AS, Sjoden GO. Case reports: Two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467(7):1921–1926.
   PubMed Web of Science ®Google Scholar
• Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int. 2009;20(8):1353–1362.
   PubMedGoogle Scholar
• Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304–1306.
   PubMed Web of Science ®Google Scholar
• Wernecke G, Namdari S, Dicarlo EF, et al. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J. 2009;5(2):204.
   Google Scholar
• Odvina CV, Levy S, Rao S, et al. Unusual mid-shaft fractures during long term Bisphosphonate therapy. Clin Endocrinol (Oxf). 2009 Mar 19. [Epub ahead of print].
   Web of Science ®Google Scholar
• Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;1:1–3.
   Google Scholar
• Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral diaphysis fracture – what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int. 2009 June 27. [Epub ahead of print].
   Web of Science ®Google Scholar
• Cermak K, Shumelinsky F, Alexiou J, et al. Case reports: Subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2009 Dec 18. [Epub ahead of print].
   Web of Science ®Google Scholar
• Pauwels F. The significance of the structural principles of the locomotor apparatus to resist the forces applied on long bones. Anat Embryol. 1948;114:1–2. German.
   Google Scholar
• Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28(5):524–531.
   PubMed Web of Science ®Google Scholar
• Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact. 2002;2:538–543.
   PubMedGoogle Scholar
• Zoehrer R, Roschger P, Paschalis EP, et al. Effects of 3-and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res. 2006;21:1106–1112.
   Web of Science ®Google Scholar
• Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci. 1984;304:509–518.
   PubMed Web of Science ®Google Scholar
• Allen MR, Gineyts E, Leeming DJ, et al. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19(3):329–337.
   PubMed Web of Science ®Google Scholar
• Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: A possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21(2):195–214.
   PubMed Web of Science ®Google Scholar
• Aspenberg P. Bisphosphonate-induced fractures: Nature strikes back? Acta Orthop. 2008;79(4):459–460.
   PubMed Web of Science ®Google Scholar
• Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009;24(12):1998–2006.
   PubMed Web of Science ®Google Scholar
• Jobke B, Pfeifer M, Minne HW. Teriparatide following bisphosphonates: Initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res. 2009;50:46–54.
   PubMed Web of Science ®Google Scholar